Omega Therapeutics, Inc. – NASDAQ:OMGA
Omega Therapeutics stock price today
$0.11
-0.71
-86.75%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Omega Therapeutics stock price monthly change
-59.31%
month
Omega Therapeutics stock price quarterly change
-59.31%
quarter
Omega Therapeutics stock price yearly change
-74.14%
year
Omega Therapeutics key metrics
Market Cap | 47.04M |
Enterprise value | 207.48M |
P/E | -2.9 |
EV/Sales | 100.04 |
EV/EBITDA | -2.14 |
Price/Sales | 123.20 |
Price/Book | 2.41 |
PEG ratio | 0.68 |
EPS | -1.67 |
Revenue | 4.93M |
EBITDA | -89.47M |
Income | -92.27M |
Revenue Q/Q | 357.36% |
Revenue Y/Y | 112.70% |
Profit margin | -4951.83% |
Oper. margin | -4954.92% |
Gross margin | 0% |
EBIT margin | -4954.92% |
EBITDA margin | -1811.64% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOmega Therapeutics stock price history
Omega Therapeutics stock forecast
Omega Therapeutics financial statements
| Jun 2023 | 759K | -29.68M | -3911.33% |
|---|---|---|---|
| Sep 2023 | 831K | -22.24M | -2677.26% |
| Dec 2023 | 989K | -20.21M | -2043.88% |
| Mar 2024 | 2.36M | -20.12M | -852.92% |
| Mar 2024 | 2.36M | -20.12M | -852.92% |
|---|---|---|---|
| Sep 2025 | 500K | -13.51M | -2702.01% |
| Oct 2025 | 778.6K | -14.94M | -1919.29% |
| Dec 2025 | 778.6K | -14.72M | -1891.1% |
Analysts Price target
Financials & Ratios estimates
| 2023-05-03 | -0.64 | -0.42 |
|---|---|---|
| 2023-05-04 | -0.64 | -0.5 |
| 2023-08-03 | -0.51 | -0.54 |
| 2023-11-09 | -0.56 | -0.4 |
| Jun 2023 | 229022000 | 133.10M | 58.12% |
|---|---|---|---|
| Sep 2023 | 217808000 | 141.76M | 65.09% |
| Dec 2023 | 204366000 | 146.35M | 71.61% |
| Mar 2024 | 183680000 | 142.32M | 77.49% |
| Jun 2023 | -23.27M | 24.04M | 219K |
|---|---|---|---|
| Sep 2023 | -23.03M | -724K | -8K |
| Dec 2023 | -17.09M | 2.14M | 1.62M |
| Mar 2024 | -11.80M | 4.46M | -1.07M |
Omega Therapeutics alternative data
| Aug 2023 | 116 |
|---|---|
| Sep 2023 | 116 |
| Oct 2023 | 116 |
| Nov 2023 | 116 |
| Dec 2023 | 116 |
| Jan 2024 | 116 |
| Feb 2024 | 116 |
| Mar 2024 | 116 |
| Apr 2024 | 116 |
| May 2024 | 93 |
| Jun 2024 | 93 |
| Jul 2024 | 93 |
Omega Therapeutics other data
30.48%
-58.69%
of OMGA is owned by hedge funds
27
-22
14.59M
-28.07M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 0 | 10000 |
| Jan 2023 | 0 | 20000 |
| Feb 2023 | 3323310 | 0 |
| Mar 2023 | 0 | 10000 |
| Apr 2023 | 0 | 5000 |
| May 2023 | 0 | 5000 |
| Jun 2023 | 0 | 5000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | YOUNG RICHARD A director | Common Stock | 5,000 | $8 | $40,000 | ||
Sale | YOUNG RICHARD A director | Common Stock | 5,000 | $8 | $40,000 | ||
Sale | YOUNG RICHARD A director | Common Stock | 5,000 | $8 | $40,000 | ||
Sale | YOUNG RICHARD A director | Common Stock | 10,000 | $8 | $80,000 | ||
Purchase | FLAGSHIP PIONEERING INC. 10 percent owner | Common Stock | 1,329,324 | $5.78 | $7,683,493 | ||
Purchase | FLAGSHIP PIONEERING INC. 10 percent owner | Common Stock | 1,993,986 | $5.78 | $11,525,239 | ||
Sale | YOUNG RICHARD A director | Common Stock | 20,000 | $8 | $160,000 | ||
Sale | YOUNG RICHARD A director | Common Stock | 10,000 | $8 | $80,000 | ||
Option | KARANDE MAHESH director, officer.. | Option (Right to Buy) | 11,300 | $0.53 | $5,989 | ||
Option | KARANDE MAHESH director, officer.. | Common Stock | 11,300 | $0.53 | $5,989 |
| Insider | Compensation |
|---|---|
| Mr. Mahesh Karande (1973) Pres, Chief Executive Officer & Board Director | $810,800 |
Dr. Thomas McCauley (1969) Chief Scientific Officer | $477,040 |
Dr. Roger Sawhney (1970) Chief Financial Officer & Treasurer | $430,680 |
-
What's the price of Omega Therapeutics stock today?
One share of Omega Therapeutics stock can currently be purchased for approximately $0.11.
-
When is Omega Therapeutics's next earnings date?
Unfortunately, Omega Therapeutics's (OMGA) next earnings date is currently unknown.
-
Does Omega Therapeutics pay dividends?
No, Omega Therapeutics does not pay dividends.
-
How much money does Omega Therapeutics make?
Omega Therapeutics has a market capitalization of 47.04M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 49.25% to 3.09M US dollars. Omega Therapeutics made a loss 97.43M US dollars in net income (profit) last year or -$0.4 on an earnings per share basis.
-
What is Omega Therapeutics's stock symbol?
Omega Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "OMGA".
-
What is Omega Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Omega Therapeutics?
Shares of Omega Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Omega Therapeutics's key executives?
Omega Therapeutics's management team includes the following people:
- Mr. Mahesh Karande Pres, Chief Executive Officer & Board Director(age: 52, pay: $810,800)
- Dr. Thomas McCauley Chief Scientific Officer(age: 56, pay: $477,040)
- Dr. Roger Sawhney Chief Financial Officer & Treasurer(age: 55, pay: $430,680)
-
How many employees does Omega Therapeutics have?
As Jul 2024, Omega Therapeutics employs 93 workers, which is 20% less then previous quarter.
-
When Omega Therapeutics went public?
Omega Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 30 Jul 2021.
-
What is Omega Therapeutics's official website?
The official website for Omega Therapeutics is omegatherapeutics.com.
-
Where are Omega Therapeutics's headquarters?
Omega Therapeutics is headquartered at 20 Acorn Park Drive, Cambridge, MA.
-
How can i contact Omega Therapeutics?
Omega Therapeutics's mailing address is 20 Acorn Park Drive, Cambridge, MA and company can be reached via phone at +61 79494360.
Omega Therapeutics company profile:
Omega Therapeutics, Inc.
omegatherapeutics.comExchange:
NASDAQ
Full time employees:
93
Industry:
Biotechnology
Sector:
Healthcare
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
20 Acorn Park Drive
Cambridge, MA 02140
Cambridge, MA 02140
CIK: 0001850838
ISIN: US68217N1054
CUSIP: 68217N105
